



Cal MediConnect – 2016

Prior Authorization Group Description

BELVIQ

Covered Uses:

As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.

Exclusion Criteria:

Required Medical Information:

BMI is greater than or equal to 30 kg/m² OR BMI is greater than or equal to 27 kg/m² with one or more of the following severe co-morbid conditions 1. Coronary artery/heart disease 2. Diabetes 3. Dyslipidemia 4. Hypertension 5. Obstructive sleep apnea AND Documentation of the patient's baseline weight is required to determine response to therapy.

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

3 months. If greater than 5% weight loss is not achieved at week 12, then drug must be discontinued. If greater than 5% weight loss is achieved then an additional 12 weeks will be approved. Reauthorization: Documentation of a 5% weight loss during the previous 6 month period for the first year of treatment. Therapy beyond the first year can be authorized every 6 months with documentation of weight maintenance.

Other Criteria: